A survey of medical directors of life insurance companies concerning use of genetic information.
Rapid advances in our ability to test persons presymptomatically for genetic diseases have generated increasing concern that genetic information will be abused by insurance companies.
Reasoning that the insurance companies may have the strongest interest in using genetic data and that the medical directors of those companies with responsibility for rating applicants would be a good source of information on the use of such data, we conducted a large survey of medical directors of North American life insurance companies.
We received responses from 27 medical directors.
Mots-clés Pascal : Maladie héréditaire, Dépistage, Diagnostic, Asymptomatique, Homme, Assurance vie, Direction entreprise, Questionnaire, Secret medical, Connaissance, Discrimination
Mots-clés Pascal anglais : Genetic disease, Medical screening, Diagnosis, Asymptomatic, Human, Life insurance, Firm leadership, Questionnaire, Medical confidentiality, Knowledge, Discrimination
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0558587
Code Inist : 002B23A. Création : 199406.